RJA
SRPT icon

Raymond James & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Raymond James & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-23,100
Closed -$148K – 3688
2020
Q2 		$148K Hold
23,100
– – ﹤0.01% 3211
2020
Q1 		$394K Hold
23,100
– – ﹤0.01% 2585
2019
Q4 		$264K Buy
23,100
+1,100
+5% +$111K ﹤0.01% 3158
2019
Q3 		$409K Sell
22,000
-1,500
-6% -$177K ﹤0.01% 2799
2019
Q2 		$209K Buy
+23,500
New +$2.86M ﹤0.01% 3228

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raymond James & Associates's SRPT Position: Q3 2024 in Review

Raymond James & Associates increased its Sarepta Therapeutics (SRPT) stake by 19% in Q3 2024, buying an estimated $562K and bringing the position to 25,713 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Raymond James & Associates first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $6.13M in Q4 2020. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Raymond James & Associates held 25,713 shares of Sarepta Therapeutics worth $3.21M as of Q3 2024.
  • Raymond James & Associates bought 4,065 Sarepta Therapeutics shares in Q3 2024, an estimated $562K.
  • Sarepta Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1928 holding.
  • Raymond James & Associates first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • Raymond James & Associates's Sarepta Therapeutics position peaked at $6.13M in Q4 2020.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.